Stocks · News reference
Top analysts change outlook on top names. Baird, Canaccord Genuity, Needham, Stifel, Truist Securities raise price targets. See analyst ratings.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The article covers various investment themes and sectors including robotics and AI adoption, pharmaceuticals driven by aging populations, airline industry opportunities, and oil/natural gas earnings growth. It also discusses employment data showing Leisure & Hospitality leading job growth, and provides analysis of major tech companies like Amazon, AbbVie, and Alibaba facing different growth drivers and challenges.
AbbVie has successfully diversified beyond its blockbuster Humira with strong immunology drugs (Skyrizi and Rinvoq), while Pfizer is leveraging its cash position to build oncology and GLP-1 pipelines. Despite AbbVie's stronger growth trajectory, Pfizer offers better valuation metrics with lower P/E and P/S ratios, making it the preferred choice for long-term value investors willing to wait for new product launches.
The article covers various market developments including August employment data expectations (55,000 new jobs, 4.2% unemployment rate), sector performance with Leisure & Hospitality leading job growth, and analysis of multiple stock sectors including biotech, gold stocks, airlines, and pharmaceuticals. It also discusses Space ETFs and various investment opportunities across different market segments.
The article covers various market developments including August employment data expectations (55,000 new jobs, 4.2% unemployment rate), sector performance with Leisure & Hospitality leading job growth, and analysis of multiple stock sectors including biotech, gold stocks, airlines, and pharmaceuticals. It also discusses Space ETFs and various investment opportunities across different market segments.
https://www.spglobal.com/spdji/en//documents/indexnews/announcements/20260904-1484999/1484999_shuffle5461-sept2026.pdf
AGNC Investment closed at $10.94, up 1.2% and outpacing the S&P 500's 0.72% gain. The REIT is expected to report EPS of $0.39 (up 11.43% YoY) and revenue of $428.4 million (up 189.46% YoY). However, the stock has lagged over the past month and carries a Zacks Rank #3 (Hold) rating with a Forward P/E of 6.78, trading at a discount to its industry average.